CA-19-9 Antigen

"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.

Descriptor ID	D018395
MeSH Number(s)	D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
Concept/Terms	CA-19-9 Antigen CA-19-9 Antigen Antigen, CA-19-9 CA 19 9 Antigen CA 19.9 Antigen Antigen, CA 19.9 Gastrointestinal Cancer Antigen Cancer Antigen, Gastrointestinal CA 19-9 Antigen Antigen, CA 19-9 Antigen CA-19-9 Antigen CA 19 9 CA-19-9, Antigen

Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".

Chemicals and Drugs [D]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
CA-19-9 Antigen [D23.050.285.050.119]
Antigens, Surface [D23.050.301]
Blood Group Antigens [D23.050.301.290]
Lewis Blood-Group System [D23.050.301.290.544]
CA-19-9 Antigen [D23.050.301.290.544.119]
Epitopes [D23.050.550]
Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
CA-19-9 Antigen [D23.050.550.325.119]
Isoantigens [D23.050.705]
Blood Group Antigens [D23.050.705.230]
Lewis Blood-Group System [D23.050.705.230.544]
CA-19-9 Antigen [D23.050.705.230.544.119]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
CA-19-9 Antigen [D23.101.140.075.119]

Below are MeSH descriptors whose meaning is related to "CA-19-9 Antigen".

Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.

Bar chart showing 11 publications over 6 distinct years, with a maximum of 3 publications in 2004 and 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2004	1	2	3
2006	1	2	3
2008	1	0	1
2011	0	1	1
2012	1	1	2

Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.

Auriemma WS, Berger AC, Bar-Ad V, Boland PM, Cohen SJ, Roche-Lima CM, Morris GJ. Locally advanced pancreatic cancer. Semin Oncol. 2012 Aug; 39(4):e9-22.

View in: PubMed
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, Macdonald J, Willett CG. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 =90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 1; 84(3):e291-7.

View in: PubMed
Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011; 45:301-21.

View in: PubMed
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008 Dec 20; 26(36):5918-22.

View in: PubMed
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20; 24(33):5313-27.

View in: PubMed
Ambro CM, Humphreys TR, Lee JB. Epidermotropically metastatic pancreatic adenocarcinoma. Am J Dermatopathol. 2006 Feb; 28(1):60-2.

View in: PubMed
Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006 Jan 15; 12(2):442-6.

View in: PubMed
Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004 Jul; 11(7):644-9.

View in: PubMed
Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004 Apr 1; 10(7):2386-92.

View in: PubMed
Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004 Feb 1; 10(3):860-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement